Efficacy and Safety of Drug-Eluting Stents in Chronic Total Coronary Occlusion Recanalization A Systematic Review and Meta-Analysis

被引:102
作者
Colmenarez, Humberto J.
Escaned, Javier [1 ]
Fernandez, Cristina [2 ]
Lobo, Liliana
Cano, Sara [2 ]
del Angel, Juan G.
Alfonso, Fernando
Jimenez, Pilar
Banuelos, Camino
Gonzalo, Nieves
Garcia, Eulogio
Hernandez, Rosana
Macaya, Carlos
机构
[1] Hosp Clin San Carlos, Unidad Cardiol Intervencionista, Cardiovasc Inst, Madrid 28040, Spain
[2] Hosp Clin San Carlos, Prevent Med Unit, Madrid 28040, Spain
关键词
chronic total occlusion; drug-eluting stent; meta-analysis; stent; BARE-METAL; FOLLOW-UP; ANGIOGRAPHIC OUTCOMES; BALLOON ANGIOPLASTY; CLINICAL-OUTCOMES; IMPLANTATION; SIROLIMUS; ARTERIES; INTERVENTION;
D O I
10.1016/j.jacc.2009.12.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study was to compare the efficacy and safety of drug-eluting stent (DES) and bare-metal stent (BMS) use in chronic total occlusion (CTO) recanalization. Background The long-term effectiveness and safety of DES use in CTO recanalization are unclear, and performance of randomized clinical trials in the field is complex. Methods Major electronic information sources were explored for articles comparing outcomes with DES and BMS use among patients with CTO. Assessed clinical outcomes were death, myocardial infarction, target vessel revascularization, major adverse cardiac events, and stent thrombosis; angiographic outcomes were stent restenosis and stent reocclusion. Results Fourteen comparative studies were identified (a total of 4,394 patients). When compared with BMS, DES significantly reduced risk of major adverse cardiac events (relative risk [RR]: 0.45, 95% confidence interval [CI]: 0.34 to 0.60, p < 0.001) and TVR (RR: 0.40, 95% CI: 0.28 to 0.58, p < 0.001) without increasing death (RR: 0.87, 95% CI: 0.66 to 1.16, p = 0.88) or myocardial infarction (RR: 0.89, 95% CI: 0.54 to 1.46, p = 0.80). This benefit was sustained at >= 3 years of follow-up. Lower RRs for restenosis (RR: 0.25, 95% CI: 0.16 to 0.41, p < 0.001) and stent reocclusion (RR: 0.30, 95% CI: 0.18 to 0.49, p < 0.001) were also observed in the DES group. A strong trend toward a higher rate of stent thrombosis was documented in DES-treated patients (RR: 2.79, 95% CI: 0.98 to 7.97, p = 0.06). Conclusions DES use in CTO recanalization is associated with significantly fewer major adverse cardiac events and fewer occurrences of target vessel revascularization, restenosis, and stent reocclusion than with BMS. Although a statistical trend toward a higher risk of stent thrombosis was observed, the use of DES in this context seems to be safe, with an overall benefit sustained in the long term. (J Am Coll Cardiol 2010; 55: 1854-66) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:1854 / 1866
页数:13
相关论文
共 31 条
  • [1] ALEKSIADI ER, 2007, GEORGIAN MED NEWS, V148, P10
  • [2] The "Vulnerable" stent - Why so dreadful?
    Alfonso, Fernando
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (25) : 2403 - 2406
  • [3] [Anonymous], NEW CASTLE OTTAWA SC
  • [4] Azzarelli S, 2008, J INVASIVE CARDIOL, V20, P62
  • [5] Primary stenting versus balloon angioplasty in occluded coronary arteries - The total occlusion study of Canada (TOSCA)
    Buller, CE
    Dzavik, V
    Carere, RG
    Mancini, GBJ
    Barbeau, G
    Lazzam, C
    Anderson, TJ
    Knudtson, ML
    Marquis, JF
    Suzuki, T
    Cohen, EA
    Fox, RS
    Teo, KK
    [J]. CIRCULATION, 1999, 100 (03) : 236 - 242
  • [6] Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria
    Carlsson, Jorg
    James, Stefan K.
    Lindback, Johan
    Schersten, Fredrik
    Nilsson, Tage
    Stenestrand, Ulf
    Lagerqvist, Bo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (16) : 1389 - 1398
  • [7] Clinical end points in coronary stent trials - A case for standardized definitions
    Cutlip, Donald E.
    Windecker, Stephan
    Mehran, Roxana
    Boam, Ashley
    Cohen, David J.
    van Es, Gerrit-Anne
    Steg, P. Gabriel
    Morel, Marie-angele
    Mauri, Laura
    Vranckx, Pascal
    McFadden, Eugene
    Lansky, Alexandra
    Hamon, Martial
    Krucoff, Mitchell W.
    Serruys, Patrick W.
    [J]. CIRCULATION, 2007, 115 (17) : 2344 - 2351
  • [8] Clinical outcome of patients with chronic total occlusion treated with drug-eluting stents
    De Felice, Francesco
    Fiorilli, Rosario
    Parma, Antonio
    Menichelli, Maurizio
    Nazzaro, Marco Stefano
    Pucci, Edoardo
    Dibra, Alban
    Musto, Carmine
    Violini, Roberto
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 132 (03) : 337 - 341
  • [9] Di Mario Carlo, 2007, EuroIntervention, V3, P30
  • [10] Three-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents:: Insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital -: (RESEARCH) registry
    Garcia-Garcia, Hector M.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 70 (05) : 635 - 639